GSK Says FDA Rejected Zofran Label Change

By Emily Field · November 10, 2020, 10:06 PM EST

GlaxoSmithKline on Monday told a Massachusetts federal judge overseeing multidistrict litigation over its anti-nausea medicine Zofran that the U.S. Food and Drug Administration has rejected a proposed label change that would...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Notice

Case Information

Case Title

In Re: Zofran (Ondansetron)Products Liability Litigation

Case Number

Court

Massachusetts

Nature of Suit

Personal Injury: Health Care/Pharmaceutical Personal Injury Product Liability

Date Filed

October 13, 2015

Recent Articles By Emily

November 05, 2024
Target Inks Individual Deals Over 'Non-Drowsy' Flu Medicine
October 10, 2024
Animal Medication Co. Sued Over Dog Arthritis Treatment Risks
August 26, 2024
Rival Can't Avoid Drugmaker's False Ad Claim Over Pain Med
August 21, 2024
Spine Implant Caused Patient's TB, Suit Says
July 23, 2024
Meet The Lead Ozempic Lawyers
June 24, 2024
Ark. AG Sues Pharmacy Benefit Managers Over Opioids
May 03, 2024
6 States Strike $270M Opioid Deal With Amneal
April 17, 2024
FDA's Foot-Dragging On Menthol Ban Sparks Frustration
March 26, 2024
Opioid Public Nuisance Claims 'Unique,' Ohio High Court Told
March 25, 2024
What To Watch As Opioid Litigation Goes To Ohio High Court